Acrivon Therapeutics (ACRV) Cash from Financing Activities (2021 - 2026)
Acrivon Therapeutics (ACRV) posted quarterly Cash from Financing Activities of -$33000.0 for Q1 2026, up 90.38% year-over-year from -$17333.8 in Q1 2025, and up 82.81% quarter-over-quarter from -$192000.0 in Q4 2025.
Acrivon Therapeutics (ACRV) Cash from Financing Activities (2021 - 2026) Analysis & Trends
Acrivon Therapeutics (ACRV) has reported Cash from Financing Activities for 6 consecutive years, with -$33000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 90.38% year-over-year to -$33000.0; the TTM figure through Mar 2026 stood at -$439000.0 (down 100.36% YoY), while the FY2025 annual figure was -$749000.0, down 100.62% from the prior year.
- Cash from Financing Activities rose to -$33000.0 in Q1 2026 per ACRV's latest filing, from -$192000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $123.4 million in Q2 2024 and bottomed at -$2.0 million in Q4 2023.
- Historically, Cash from Financing Activities has averaged $16.9 million across 5 years, with a median of -$140000.0 in 2022.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities surged 155.71% — and 2024, when it tumbled 2028.21%.
- Acrivon Therapeutics' Cash from Financing Activities stood at $101.9 million in 2022, then plunged by 101.97% to -$2.0 million in 2023, then soared by 67.83% to -$647000.0 in 2024, then jumped by 70.32% to -$192000.0 in 2025, then soared by 82.81% to -$33000.0 in 2026.
- Business Quant data shows ACRV's Cash from Financing Activities at -$33000.0 in Q1 2026, -$192000.0 in Q4 2025, and -$117000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Acrivon Therapeutics | 92.89 Mn | 92.89 Mn | - | 7.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.27 Mn |
| Jun 30, 2026 | 7.27 Mn |
| Mar 31, 2026 | -33,000.00 |
| Mar 31, 2026 | -33,000.00 |
| Dec 31, 2025 | -192,000.00 |
| Dec 31, 2025 | -192,000.00 |
| Sep 30, 2025 | -117,000.00 |
| Sep 30, 2025 | -117,000.00 |
| Jun 30, 2025 | -97,000.00 |
| Jun 30, 2025 | -97,000.00 |
| Mar 31, 2025 | -343,000.00 |
| Mar 31, 2025 | -343,000.00 |
| Dec 31, 2024 | -647,000.00 |
| Dec 31, 2024 | -647,000.00 |
| Sep 30, 2024 | -1.50 Mn |
| Sep 30, 2024 | -1.50 Mn |
| Jun 30, 2024 | 123.35 Mn |
| Jun 30, 2024 | 123.35 Mn |
| Mar 31, 2024 | -172,000.00 |
| Mar 31, 2024 | -172,000.00 |